Gilead taps Korea's Yuhan to supply HIV drug ingredients in $81M …
WEB4 hours ago · The deal amount represents 5.8% of Yuhan’s latest yearly sales of 1.85 trillion Korean won ($1.4 billion), according to a filing. Yuhan co-promotes several Gilead HIV drugs, including the ...
Yuhan, Janssen halt next-gen cancer drug collaboration - The …
WEB11 hours ago · Yuhan's corporate logo (Yuhan) South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the development of a next-generation targeted ...
Yuhan inks $80.9 million deal with Gilead Sciences for HIV ... - MSN
WEBYuhan CEO Cho Wook-je speaks during a press conference held in western Seoul in August. [YONHAP] Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ...
Yuhan inks $81 mn contract with U.S. Gilead to supply HIV …
WEB19 hours ago · South Korean pharmaceutical company Yuhan Corp. announced on Friday that it has signed a contract with U.S. biopharmaceutical company Gilead Sciences Inc. to supply raw materials for human immunodeficiency virus (HIV) treatments. The contract is worth 107.6 billion won ($80.8 million), which is 5.79 percent of Yuhan’s sales in 2023.
Yuhan Corporation and J INTS BIO inked a licensing agreement …
WEBSEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a...
Yuhan Shares Jump 4% After US FDA Approves Anti-Cancer Drug …
WEBAug 21, 2024 · Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. -- Shares of Yuhan jumped more than 4% in recent trade after the U.S. Food and Drug Administration approved RYBREVANT, or amivantamab-vmjw plus LAZCLUZE, or lazertinib, for patients suffering from...
Yuhan ends cancer project with J&J as it signs API deal with …
WEB4 hours ago · Anna Brown. News Reporter. Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing approval in ...
[Herald Interview] Yuhan aims for bigger presence in US
WEBJan 11, 2023 · SAN FRANCISCO – South Korean pharmaceutical giant Yuhan is seeking to increase cooperation with researchers and biotechnology firms based in the US, with hopes to benefit from the nation’s...
[INTERVIEW] Yuhan USA is searching for its next promising …
WEBJan 11, 2023 · Yuhan, a Seoul-based biopharmaceutical company best known for its licensing of a novel lung cancer treatment called lazertinib, sold under brand Leclaza, has clinched a deal with Yansen to export the drug and is now looking for its next target.
Yonhap News Agency
WEB1 day ago · Yonhap News Agency. #N Korea. N. Korea fires multiple short-range ballistic missiles: JCS. North Korea fired multiple short-range ballistic missiles in a northeastern direction on Wednesday, South Korea's military said, further ratcheting up tensions already heightened b... Just now. N. Korean missiles flew about 400 km: JCS.